Evolutionary Approaches to Combat Antibiotic Resistance: Opportunities and Challenges for Precision Medicine.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2020
Historique:
received: 01 06 2020
accepted: 17 07 2020
entrez: 28 9 2020
pubmed: 29 9 2020
medline: 20 4 2021
Statut: epublish

Résumé

The rise of antimicrobial resistance (AMR) in bacterial pathogens is acknowledged by the WHO as a major global health crisis. It is estimated that in 2050 annually up to 10 million people will die from infections with drug resistant pathogens if no efficient countermeasures are implemented. Evolution of pathogens lies at the core of this crisis, which enables rapid adaptation to the selective pressures imposed by antimicrobial usage in both medical treatment and agriculture, consequently promoting the spread of resistance genes or alleles in bacterial populations. Approaches developed in the field of Evolutionary Medicine attempt to exploit evolutionary insight into these adaptive processes, with the aim to improve diagnostics and the sustainability of antimicrobial therapy. Here, we review the concept of evolutionary trade-offs in the development of AMR as well as new therapeutic approaches and their impact on host-microbiome-pathogen interactions. We further discuss the possible translation of evolution-informed treatments into clinical practice, considering both the rapid cure of the individual patients and the prevention of AMR.

Identifiants

pubmed: 32983122
doi: 10.3389/fimmu.2020.01938
pmc: PMC7481325
doi:

Substances chimiques

Anti-Bacterial Agents 0
Bacterial Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1938

Informations de copyright

Copyright © 2020 Merker, Tueffers, Vallier, Groth, Sonnenkalb, Unterweger, Baines, Niemann and Schulenburg.

Références

N Engl J Med. 2015 Nov 12;373(20):1986-8
pubmed: 26559594
Nat Genet. 2011 Dec 18;44(1):106-10
pubmed: 22179134
Elife. 2018 Dec 18;7:
pubmed: 30560781
Cancer Res. 2018 May 1;78(9):2419-2431
pubmed: 29686021
Nature. 2011 Aug 31;477(7365):457-61
pubmed: 21881561
Drug Resist Updat. 2019 May;44:100640
pubmed: 31492517
PLoS Biol. 2018 Apr 30;16(4):e2004356
pubmed: 29708964
PLoS Biol. 2020 Apr 20;18(4):e3000465
pubmed: 32310938
Infect Immun. 2002 Sep;70(9):4955-60
pubmed: 12183541
Mol Biol Evol. 2017 Sep 1;34(9):2229-2244
pubmed: 28541480
Int J Antimicrob Agents. 2016 Jan;47(1):48-55
pubmed: 26597931
Molecules. 2018 Mar 30;23(4):
pubmed: 29601469
Lancet Infect Dis. 2013 Feb;13(2):155-65
pubmed: 23347633
FEMS Microbiol Rev. 2020 Mar 1;44(2):171-188
pubmed: 31981358
Elife. 2019 Sep 13;8:
pubmed: 31516122
Nat Rev Microbiol. 2010 Apr;8(4):260-71
pubmed: 20208551
ISME J. 2012 Jul;6(7):1345-55
pubmed: 22278669
Evol Appl. 2015 Mar;8(3):273-83
pubmed: 25861385
Cell Host Microbe. 2015 Sep 9;18(3):307-19
pubmed: 26299432
Nat Commun. 2019 Jan 18;10(1):334
pubmed: 30659188
Br Med J. 1913 Aug 16;2(2746):353-9
pubmed: 20766753
PLoS Biol. 2013;11(4):e1001540
pubmed: 23630452
Mucosal Immunol. 2019 Jan;12(1):1-9
pubmed: 29988120
ISME J. 2018 Jun;12(6):1582-1593
pubmed: 29563570
Gut. 2020 Aug;69(8):1510-1519
pubmed: 32409589
Mol Microbiol. 2002 Oct;46(2):355-66
pubmed: 12406214
PLoS Biol. 2019 Oct 25;17(10):e3000515
pubmed: 31652256
Trends Microbiol. 2015 Mar;23(3):126-33
pubmed: 25680587
Mol Microbiol. 2014 Mar;91(6):1106-19
pubmed: 24417450
PLoS Comput Biol. 2018 Jun 21;14(6):e1006179
pubmed: 29927925
PLoS Pathog. 2015 Jul 02;11(7):e1005008
pubmed: 26133982
Nature. 2004 Aug 26;430(7003):1024-7
pubmed: 15329720
Elife. 2018 Dec 18;7:
pubmed: 30558711
Curr Opin Microbiol. 2015 Oct;27:1-9
pubmed: 26042389
Antimicrob Agents Chemother. 2004 May;48(5):1797-802
pubmed: 15105137
Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14607-12
pubmed: 11717398
Mol Syst Biol. 2013 Aug 06;9:683
pubmed: 23917989
Nat Rev Immunol. 2012 Apr 20;12(5):352-66
pubmed: 22517424
Biotechnol Adv. 2019 Jan - Feb;37(1):177-192
pubmed: 30500353
Nat Rev Microbiol. 2009 Jun;7(6):460-6
pubmed: 19444248
Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):13977-81
pubmed: 18779569
PLoS One. 2013;8(2):e56858
pubmed: 23441219
Mol Biol Evol. 2014 Sep;31(9):2387-401
pubmed: 24962091
Evol Appl. 2009 Feb;2(1):40-51
pubmed: 25567846
Elife. 2018 Oct 30;7:
pubmed: 30373719
Genome Biol Evol. 2014 May 20;6(6):1287-301
pubmed: 24850796
Microorganisms. 2016 Feb 16;4(1):
pubmed: 27681908
BMC Infect Dis. 2009 Dec 14;9:202
pubmed: 20003454
Microbiol Spectr. 2016 Apr;4(2):
pubmed: 27227291
Evol Appl. 2015 Dec;8(10):945-55
pubmed: 26640520
Res Microbiol. 2004 Jun;155(5):360-9
pubmed: 15207868
Nat Commun. 2018 Sep 10;9(1):3673
pubmed: 30202004
J Antimicrob Chemother. 2019 Oct 1;74(10):2916-2925
pubmed: 31355848
Science. 2008 Jul 18;321(5887):365-7
pubmed: 18635792
ISME J. 2019 Dec;13(12):2927-2937
pubmed: 31384011
Curr Biol. 2020 Mar 23;30(6):1049-1062.e7
pubmed: 32142697
Mol Biol Evol. 2015 May;32(5):1175-85
pubmed: 25618457
Sci Transl Med. 2013 Sep 25;5(204):204ra132
pubmed: 24068739
J Mol Med (Berl). 2012 May;90(5):509-22
pubmed: 22544168
J Antimicrob Chemother. 2000 Jan;45(1):9-13
pubmed: 10629007
Science. 2006 Jun 30;312(5782):1944-6
pubmed: 16809538
Clin Microbiol Rev. 2017 Nov 29;31(1):
pubmed: 29187395
J Bacteriol. 1952 Oct;64(4):489-99
pubmed: 12999676
Cell. 2018 Jan 11;172(1-2):121-134.e14
pubmed: 29307490
Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):9442-7
pubmed: 26170289
Antimicrob Agents Chemother. 2013 Feb;57(2):827-32
pubmed: 23208709
Evol Med Public Health. 2019 Feb 22;2019(1):37-45
pubmed: 30906555
Proc Natl Acad Sci U S A. 2018 Sep 25;115(39):9767-9772
pubmed: 30209218
Elife. 2019 Oct 29;8:
pubmed: 31658946
Mol Syst Biol. 2013 Oct 29;9:700
pubmed: 24169403
Proc Natl Acad Sci U S A. 2019 Jan 22;116(4):1378-1383
pubmed: 30626645
Proc Natl Acad Sci U S A. 2015 Aug 25;112(34):10756-61
pubmed: 26240352

Auteurs

Matthias Merker (M)

Molecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany.
German Center for Infection Research (DZIF), Partner Site Borstel-Hamburg-Lübeck-Riems, Hamburg, Germany.
Cluster of Excellence Precision Medicine in Chronic Inflammation, Kiel, Germany.

Leif Tueffers (L)

Cluster of Excellence Precision Medicine in Chronic Inflammation, Kiel, Germany.
Evolutionary Ecology and Genetics, Zoological Institute, Christian-Albrechts-Universität, Kiel, Germany.

Marie Vallier (M)

Cluster of Excellence Precision Medicine in Chronic Inflammation, Kiel, Germany.
Section of Evolutionary Medicine, Institute for Experimental Medicine, Kiel University and Max Planck Institute for Evolutionary Biology, Plön, Germany.

Espen E Groth (EE)

Cluster of Excellence Precision Medicine in Chronic Inflammation, Kiel, Germany.
Evolutionary Ecology and Genetics, Zoological Institute, Christian-Albrechts-Universität, Kiel, Germany.
Department of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany.

Lindsay Sonnenkalb (L)

Molecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany.

Daniel Unterweger (D)

Cluster of Excellence Precision Medicine in Chronic Inflammation, Kiel, Germany.
Section of Evolutionary Medicine, Institute for Experimental Medicine, Kiel University and Max Planck Institute for Evolutionary Biology, Plön, Germany.

John F Baines (JF)

Cluster of Excellence Precision Medicine in Chronic Inflammation, Kiel, Germany.
Section of Evolutionary Medicine, Institute for Experimental Medicine, Kiel University and Max Planck Institute for Evolutionary Biology, Plön, Germany.

Stefan Niemann (S)

Molecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany.
German Center for Infection Research (DZIF), Partner Site Borstel-Hamburg-Lübeck-Riems, Hamburg, Germany.
Cluster of Excellence Precision Medicine in Chronic Inflammation, Kiel, Germany.

Hinrich Schulenburg (H)

Cluster of Excellence Precision Medicine in Chronic Inflammation, Kiel, Germany.
Evolutionary Ecology and Genetics, Zoological Institute, Christian-Albrechts-Universität, Kiel, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH